# NM_001196.4(BID):c.188G>C (p.Arg63Pro)

https://sugi.bio/variant/bid-p-arg63pro

## Summary

**BID p.Arg63Pro (c.188G>C)** is classified **Uncertain significance** in BID (ClinVar, Single submitter, 1 submitter; last evaluated 2024-02-14). AlphaMissense: likely pathogenic (0.6098); Very rare (popmax 0.0017%, nfe).

**At a glance:** Uncertain significance · review: Single submitter · rsID rs771344517 · 1 submitter · AlphaMissense likely pathogenic · very rare (popmax 0.0017%, nfe)

## For patients & families {#patients}

This is a change in the BID gene that is currently of uncertain significance — a definitive interpretation has not yet been established, submitted by 1 submitter.

*Reference information, not medical advice, and not a prediction for any individual. A genetic counselor or clinician can interpret what it means for you and your family.*

**Support & next steps:** [Find a genetic counselor (NSGC)](https://findageneticcounselor.nsgc.org/).

## Identity {#identity}

| Field | Value |
| --- | --- |
| Gene | [BID](https://sugi.bio/atlas/gene/BID/) |
| Protein change (HGVS p.) | p.Arg63Pro |
| Coding change (HGVS c.) | c.188G>C |
| MANE Select transcript | [NM_001196](https://www.ncbi.nlm.nih.gov/nuccore/NM_001196) |
| dbSNP | [rs771344517](https://www.ncbi.nlm.nih.gov/snp/rs771344517/) |
| Variant type | single nucleotide variant |
| Location | chr22:17743838-17743838 (GRCh38) |
| ClinVar | [VCV3133988](https://www.ncbi.nlm.nih.gov/clinvar/variation/3133988/) |

**All HGVS expressions:** `NC_000022.10:g.18226604C>G`, `NC_000022.11:g.17743838C>G`, `NM_001196.4:c.188G>C`, `NM_001244567.2:c.188G>C`, `NM_001244569.1:c.-65-4350G>C`, `NM_001244570.1:c.-65-4350G>C`, `NM_001244572.1:c.-65-4350G>C`, `NM_197966.3:c.326G>C`, `NM_197967.3:c.-101G>C`

## Computational & population evidence {#evidence}

**Concordance:** Mixed / partial computational evidence (see below).

- AlphaMissense **likely pathogenic** (0.6098)
- REVEL 0.236 (benign-leaning) — differs from AlphaMissense
- SaProt LLR -6.239 (tolerated) — differs from AlphaMissense
- → **In-silico consensus:** AlphaMissense calls this damaging; REVEL and SaProt do not
- Conservation: phyloP -0.393, GERP -3.11 — not a conserved position (phyloP < 0.1, ACGS BP7 cut)
- CADD: **PHRED 15.53**. No single ClinGen-calibrated threshold exists and the expert panels that use CADD disagree — GUCY2D/AIPL1 require ≥ 20.0 for an untranslated-region variant, ABCA4 ≥ 28.1 for a synonymous or indel variant, the Pulmonary Hypertension panel imports Pejaver 2022's missense-calibrated numbers, and the Antibody Deficiencies panel declines CADD entirely for PIK3CD. CADD v1.7 also incorporates Zoonomia phyloP, so it partly re-expresses the conservation above. *Descriptive; no threshold applied.*
- Regional missense constraint: **o/e 0.88** across the covering region of the MANE Select transcript (17,735,583–17,750,116), spanning 14,533 bp. Chi-square p 0.061. Describes the region, not this allele; gnomAD v4.1.1's own constrained determination. *Descriptive; no ACMG code applied.*
- SpliceAI: **not assessed** — no allele at this position is in our SpliceAI release, either because it lies outside the scored MANE transcript scope or because every allele is below Δ0.2. We cannot tell which, so this claims neither; absence is not evidence against a splicing effect.
- Population frequency (gnomAD v4.1): grpmax **0.0017%** (nfe) · FAF95 0.00111% · FAF99 0.0009% · 20/1,179,616 in the highest group · 103/1,611,580 alleles overall — very rare (popmax 0.0017%, nfe).

| Ancestry group | Allele frequency | 1 in |
| --- | --- | --- |
| Finnish (not grpmax-eligible) | 0.123% | 810 |
| Remaining individuals (not grpmax-eligible) | 0.00802% | 12,461 |
| European (non-Finnish) (grpmax) | 0.0017% | 58,981 |
| African / African-American | 0.00133% | 74,912 |

Finnish shows a higher raw frequency than the grpmax group. gnomAD excludes bottlenecked groups — Finnish, Ashkenazi Jewish, Amish and "Remaining individuals" — from grpmax, because founder effects make their frequencies unrepresentative for filtering. The table is sorted by frequency, so an excluded group can sit above the grpmax row.

*Computational predictors are not independent (ClinGen Variant Classification guidance): AlphaMissense (Cheng et al. 2023) carries the ACMG weight for missense and conservation (phyloP/GERP/phastCons) for non-missense; REVEL (Pejaver-2022 calibrated strength bands) and SaProt (Su et al. 2023, structure-aware, ClinVar-independent protein language model, raw LLR) are shown as orthogonal agreement signals, not additive. For frequency, the gnomAD v4.1 grpmax filtering allele frequency (FAF95) is ClinGen's designated BA1/BS1 input (gnomAD v4 guidance v3.0, June 2025); BA1/BS1 thresholds are disease-specific, not a blanket 5%. Predictions, not a clinical determination.*

## Gene constraint & dosage {#gene-context}

**BID** population constraint: LOEUF 1.553, pLI 1.4101e-07, missense-Z 0.73267. *Lower LOEUF and higher pLI indicate a gene that tolerates loss-of-function poorly; ClinGen dosage is the curated haploinsufficiency call.*

## Protein context {#protein}


AlphaFold model confidence (whole protein): pLDDT 63.12, 0% of residues very-high.

**17 experimental structure(s)** (PDB): [1ZY3](https://www.rcsb.org/structure/1ZY3), [2BID](https://www.rcsb.org/structure/2BID), [2KBW](https://www.rcsb.org/structure/2KBW), [2M5B](https://www.rcsb.org/structure/2M5B), [2M5I](https://www.rcsb.org/structure/2M5I), [4BD2](https://www.rcsb.org/structure/4BD2).

## What this gene does {#gene-function}

*Describes the biological roles of BID (the gene this variant disrupts) — not effects measured for this specific variant. A damaging variant is expected to affect these functions and pathways; the degree depends on the variant.*


### Pathways affected {#pathways}

BID participates in **6 Reactome pathways** (⚕ = disease pathway):

| Pathway (Reactome) | Evidence |
| --- | --- |
| [Activation and oligomerization of BAK protein](https://reactome.org/content/detail/R-HSA-111452) | curated |
| [Activation of BAD and translocation to mitochondria ](https://reactome.org/content/detail/R-HSA-111447) | curated |
| [Activation, myristolyation of BID and translocation to mitochondria](https://reactome.org/content/detail/R-HSA-75108) | curated |
| [Activation, translocation and oligomerization of BAX](https://reactome.org/content/detail/R-HSA-114294) | curated |
| [BH3-only proteins associate with and inactivate anti-apoptotic BCL-2 members](https://reactome.org/content/detail/R-HSA-111453) | curated |
| [TP53 Regulates Transcription of Genes Involved in Cytochrome C Release](https://reactome.org/content/detail/R-HSA-6803204) | curated |

### Molecular function & processes (GO — experimentally supported) {#go}

**Biological process:** release of cytochrome c from mitochondria, positive regulation of protein-containing complex assembly, positive regulation of apoptotic process, establishment of protein localization to membrane, positive regulation of release of cytochrome c from mitochondria, hepatocyte apoptotic process.

## Clinical significance {#significance}

**Uncertain significance** — review status Single submitter *(criteria provided, single submitter)*, last evaluated 2024-02-14.

**Submitter consensus:** unanimous (1/1 Uncertain significance).

### Submitter classifications {#submitters}

| Submitter | Classification | Review | Method | Date |
| --- | --- | --- | --- | --- |
| Ambry Genetics | Uncertain significance | criteria provided, single submitter | clinical testing | 2024-02-14 |

**Reported phenotype names (ClinVar):** not specified, AllHighlyPenetrant.

## Similar variants {#similar}

Related BID variant pages (same residue, condition, or type): [BID p.Arg63His](/variant/bid-p-arg63his), [BID c.-14G>A](/variant/bid-c-minus-14g-a), [BID c.-15C>T](/variant/bid-c-minus-15c-t), [BID c.-23G>A](/variant/bid-c-minus-23g-a), [BID c.-24C>G](/variant/bid-c-minus-24c-g), [BID c.-33G>A](/variant/bid-c-minus-33g-a), [BID c.-39G>A](/variant/bid-c-minus-39g-a), [BID c.-59+698A>G](/variant/bid-c-minus-59-plus-698a-g).

### Data sources & attribution {#sources}

ClinVar (NCBI — public domain, built 2026-10-14); gnomAD v4.1 (Broad Institute, built 2026-10-06); AlphaMissense (Cheng et al. 2023, © Google DeepMind — CC BY 4.0, built 2026-01-27); REVEL (Ioannidis et al. 2016 — ODbL, built 2026-07-13); SaProt (Su et al. 2023 — MIT, built 2026-10-14); SpliceAI (Illumina — free for non-commercial use, built 2026-10-13); CADD (Rentzsch et al. 2019, University of Washington — free for non-commercial use, built 2026-10-10); Conservation (phyloP/phastCons/GERP) (UCSC hg38 470-way mammal (Hiller Lab) + Ensembl Compara, built 2026-07-12); gnomAD Non-coding Constraint (Gnocchi) (Chen et al. 2024, Broad Institute — CC0, built 2026-10-11); gnomAD Regional Missense Constraint (Broad Institute — CC0, built 2026-10-13); Pangolin (Zeng & Li 2022 — CC BY 4.0, built 2026-10-11); Repeat regions (UCSC — RepeatMasker, TRF, segmental duplications, built 2026-10-11); ClinGen (ClinGen, built 2026-09-22); UniProt (CC BY 4.0); Reactome / GO (CC BY 4.0, built 2026-09-23); MaveDB (per-record license, built 2026-10-11); CIViC (CC0, built 2026-09-22); Orphanet (Orphanet, built 2026-06-12)

*Primary record: NCBI ClinVar (variation 3133988). Classifications reflect these databases as of the page's build date and may change. Free reference use — not medical advice; consult the primary submitters and a clinician.*